Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma says last subject dosed in Phase 1b norovirus challenge study

Neutral Impact 2 of 5 other Written later

Cocrystal Pharma announced on September 9, 2026 that the last subject has been dosed in its Phase 1b norovirus challenge study of CDI-988, an oral antiviral candidate. The company reported no serious adverse events to date and expects preliminary efficacy results in late 2026 or early 2027. The filing is a clinical development update and does not include financial results.

Key points

  • Last subject dosed in the Phase 1b challenge study (NCT07198139) evaluating CDI-988 as a preventive and treatment for norovirus
  • No serious adverse events reported to date
  • Preliminary efficacy results expected in late 2026 or early 2027
  • Primary endpoint is efficacy versus placebo in reducing the incidence of clinical symptoms; study conducted at Emory University School of Medicine

The filing

CompanyCocrystal Pharma, Inc. (COCP)
Form8-K, current report
Filed with the SECSep 9, 2026, 8:00 AM ET
Accession number0001493152-26-041877

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.